Oligofastx is a project born from a need: to offer a therapeutic pathway based on the development of specific oligonucleotides for certain rare diseases for which there is no solution at the moment. I feel this is our leit-motiv and sign of identity, we could not miss, of course, to join the celebration of Rare […]
Cancer cachexia is a complex metabolic syndrome characterized by marked loss of body weight, anorexia, asthenia, sarcopenia, and anemia. It is the most common manifestation of advanced malignant cancer, leading to death. Approximately half of all cancer patients experience cachexia and the prevalence is over 80% in terminally ill patients, with cachexia being responsible for […]
Perhaps the definition is not the most accurate, but in reality a rare disease does nothing more than denominate a pathology that has not yet been studied, analyzed and against which there is, for the time being, no solution. The complexity of the processes to reach social development solutions for the improvement of patients’ quality […]
Every last Sunday of September is celebrated the International Retinitis Pigmentosa Day, one of the rare and genetic diseases of the retina. Aware of the complications that the disease can bring, from Oligofastx we work together in the research and development of solutions based on the development of oligonucleotides to reach an effective treatment. This […]
Today is International Myotonic Dystrophy Day, a rare disease with no treatment or cure to date. Although Myotonic Dystrophy is not within the Oligofastx project, it is one of the diseases on which Arthex Biotech (Oligofastx partner company) is researching and working to find a therapeutic solution. Specifically, Arthex is developing an experimental RNA-based drug […]
Español